Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression.

Klümper N, Syring I, Vogel W, Schmidt D, Müller SC, Ellinger J, Shaikhibrahim Z, Brägelmann J, Perner S.

Front Med (Lausanne). 2017 Mar 17;4:30. doi: 10.3389/fmed.2017.00030. eCollection 2017.

2.

MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.

Offermann A, Vlasic I, Syring I, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Hagedorn S, Behrends J, Nowak M, Merseburger A, Bubendorf L, Kirfel J, Duensing S, Shaikhibrahim Z, Perner S.

Oncotarget. 2017 Jan 31;8(5):7964-7976. doi: 10.18632/oncotarget.13860.

3.

Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer.

Brägelmann J, Klümper N, Offermann A, von Mässenhausen A, Böhm D, Deng M, Queisser A, Sanders C, Syring I, Merseburger AS, Vogel W, Sievers E, Vlasic I, Carlsson J, Andrén O, Brossart P, Duensing S, Svensson MA, Shaikhibrahim Z, Kirfel J, Perner S.

Clin Cancer Res. 2017 Apr 1;23(7):1829-1840. doi: 10.1158/1078-0432.CCR-16-0094. Epub 2016 Sep 27.

4.

Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types.

Syring I, Klümper N, Offermann A, Braun M, Deng M, Boehm D, Queisser A, von Mässenhausen A, Brägelmann J, Vogel W, Schmidt D, Majores M, Schindler A, Kristiansen G, Müller SC, Ellinger J, Shaikhibrahim Z, Perner S.

Oncotarget. 2016 Apr 26;7(17):23043-55. doi: 10.18632/oncotarget.8469.

5.

Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.

Gelato KA, Shaikhibrahim Z, Ocker M, Haendler B.

Expert Opin Ther Targets. 2016 Jul;20(7):783-99. doi: 10.1517/14728222.2016.1134490. Epub 2016 Jan 22. Review.

PMID:
26799480
6.

MED15: a potential biomarker for head and neck squamous cell carcinoma?

Offermann A, Shaikhibrahim Z, Perner S.

Biomark Med. 2015;9(10):939-41. doi: 10.2217/bmm.15.57. Epub 2015 Oct 12. No abstract available.

7.

Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors.

Klümper N, Syring I, Offermann A, Shaikhibrahim Z, Vogel W, Müller SC, Ellinger J, Strauß A, Radzun HJ, Ströbel P, Brägelmann J, Perner S, Bremmer F.

Diagn Pathol. 2015 Sep 17;10:165. doi: 10.1186/s13000-015-0398-6.

8.

Clinical and molecular implications of MED15 in head and neck squamous cell carcinoma.

Shaikhibrahim Z, Offermann A, Halbach R, Vogel W, Braun M, Kristiansen G, Bootz F, Wenzel J, Mikut R, Lengerke C, Reischl M, Schröck A, Perner S.

Am J Pathol. 2015 Apr;185(4):1114-22. doi: 10.1016/j.ajpath.2014.12.010. Epub 2015 Mar 16.

PMID:
25791637
9.

MED12 overexpression is a frequent event in castration-resistant prostate cancer.

Shaikhibrahim Z, Offermann A, Braun M, Menon R, Syring I, Nowak M, Halbach R, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Bubendorf L, Biskup S, Duensing S, Kirfel J, Perner S.

Endocr Relat Cancer. 2014 Aug;21(4):663-75. doi: 10.1530/ERC-14-0171. Epub 2014 Jun 17.

PMID:
24938407
10.

Words of wisdom: Re: Punctuated evolution of prostate cancer genomes.

Shaikhibrahim Z, Offermann A, Perner S.

Eur Urol. 2014 Mar;65(3):666-7. doi: 10.1016/j.eururo.2013.11.022. No abstract available.

PMID:
24484760
11.

MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer.

Shaikhibrahim Z, Menon R, Braun M, Offermann A, Queisser A, Boehm D, Vogel W, Rüenauver K, Ruiz C, Zellweger T, Svensson M, Andren O, Kristiansen G, Wernert N, Bubendorf L, Kirfel J, Biskup S, Perner S.

Int J Cancer. 2014 Jul 1;135(1):19-26. doi: 10.1002/ijc.28647. Epub 2013 Dec 9.

12.

Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.

Menon R, Deng M, Rüenauver K, Queisser A, Peifer M, Offermann A, Boehm D, Vogel W, Scheble V, Fend F, Kristiansen G, Wernert N, Oberbeckmann N, Biskup S, Rubin MA, Shaikhibrahim Z, Perner S.

J Pathol. 2013 Dec;231(4):505-16. doi: 10.1002/path.4274. Erratum in: J Pathol. 2014 May;233(1):101. Pfeifer, Martin [corrected to Peifer, Martin].

PMID:
24114522
13.

Landscape of chromosome number changes in prostate cancer progression.

Braun M, Stomper J, Kirsten R, Shaikhibrahim Z, Vogel W, Böhm D, Wernert N, Kristiansen G, Perner S.

World J Urol. 2013 Dec;31(6):1489-95. doi: 10.1007/s00345-013-1051-1. Epub 2013 Mar 20.

PMID:
23512229
14.

The heterogeneous Gleason 7 carcinoma of the prostate: analyses of low and high grade (risk) carcinomas with criteria of the International Society of Urological Pathology (ISUP).

Helpap B, Ringli D, Shaikhibrahim Z, Wernert N, Kristiansen G.

Pathol Res Pract. 2013 Mar;209(3):190-4. doi: 10.1016/j.prp.2012.10.016. Epub 2013 Feb 15.

PMID:
23419692
15.

Epigenetics-related genes in prostate cancer: expression profile in prostate cancer tissues, androgen-sensitive and -insensitive cell lines.

Shaikhibrahim Z, Lindstrot A, Ochsenfahrt J, Fuchs K, Wernert N.

Int J Mol Med. 2013 Jan;31(1):21-5. doi: 10.3892/ijmm.2012.1173. Epub 2012 Nov 6.

16.

Significance of Gleason grading of low-grade carcinoma of the prostate with therapeutic option of active surveillance.

Helpap B, Kristiansen G, Köllermann J, Shaikhibrahim Z, Wernert N, Oehler U, Fellbaum C.

Urol Int. 2013;90(1):17-23. doi: 10.1159/000342810. Epub 2012 Oct 24.

PMID:
23095725
17.

ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1, in prostate cancer.

Shaikhibrahim Z, Ochsenfahrt J, Fuchs K, Kristiansen G, Perner S, Wernert N.

Int J Mol Med. 2012 Nov;30(5):1029-33. doi: 10.3892/ijmm.2012.1097. Epub 2012 Aug 20.

18.

ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer.

Scheble VJ, Scharf G, Braun M, Ruiz C, Stürm S, Petersen K, Beschorner R, Bachmann A, Zellweger T, Fend F, Kristiansen G, Bubendorf L, Wernert N, Shaikhibrahim Z, Perner S.

Virchows Arch. 2012 Aug;461(2):157-62. doi: 10.1007/s00428-012-1270-7. Epub 2012 Jul 6.

PMID:
22767266
19.

Regulation of prostate cancer immunity-related genes in PC3 prostate cancer cells by ETS-1.

Shaikhibrahim Z, Lindstrot A, Buettner R, Wernert N.

Oncol Lett. 2012 Mar;3(3):513-516. Epub 2011 Dec 2.

20.

Improved method of detecting the ERG gene rearrangement in prostate cancer using combined dual-color chromogenic and silver in situ hybridization.

Braun M, Stomper J, Boehm D, Vogel W, Scheble VJ, Wernert N, Shaikhibrahim Z, Fend F, Kristiansen G, Perner S.

J Mol Diagn. 2012 Jul;14(4):322-7. doi: 10.1016/j.jmoldx.2012.01.017. Epub 2012 May 27.

PMID:
22642898
21.

Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5, and ELK-4 is a clonal event during prostate cancer progression.

Shaikhibrahim Z, Braun M, Nikolov P, Boehm D, Scheble V, Menon R, Fend F, Kristiansen G, Perner S, Wernert N.

Hum Pathol. 2012 Nov;43(11):1910-6. doi: 10.1016/j.humpath.2012.01.018. Epub 2012 May 7.

PMID:
22569213
22.

Classifying prostate cancer malignancy by quantitative histomorphometry.

Loeffler M, Greulich L, Scheibe P, Kahl P, Shaikhibrahim Z, Braumann UD, Kuska JP, Wernert N.

J Urol. 2012 May;187(5):1867-75. doi: 10.1016/j.juro.2011.12.054. Epub 2012 Mar 16.

PMID:
22424674
23.

ETS transcription factors and prostate cancer: the role of the family prototype ETS-1 (review).

Shaikhibrahim Z, Wernert N.

Int J Oncol. 2012 Jun;40(6):1748-54. doi: 10.3892/ijo.2012.1380. Epub 2012 Feb 21. Review.

PMID:
22366814
24.

Novel identification of the ETS-1 splice variants p42 and p27 in prostate cancer cell lines.

Shaikhibrahim Z, Ochsenfahrt J, Fuchs K, Wernert N.

Oncol Rep. 2012 May;27(5):1321-4. doi: 10.3892/or.2012.1667. Epub 2012 Feb 1.

PMID:
22307076
25.

ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.

Braun M, Goltz D, Shaikhibrahim Z, Vogel W, Böhm D, Scheble V, Sotlar K, Fend F, Tan SH, Dobi A, Kristiansen G, Wernert N, Perner S.

Prostate Cancer Prostatic Dis. 2012 Jun;15(2):165-9. doi: 10.1038/pcan.2011.67. Epub 2012 Jan 10.

PMID:
22231490
26.

The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key?

Shaikhibrahim Z, Lindstrot A, Ellinger J, Rogenhofer S, Buettner R, Perner S, Wernert N.

Mol Med Rep. 2012 Feb;5(2):313-6. doi: 10.3892/mmr.2011.647. Epub 2011 Oct 27.

PMID:
22038307
27.

Genes differentially expressed in the peripheral zone compared to the transitional zone of the normal human prostate and their potential regulation by ETS factors.

Shaikhibrahim Z, Lindstrot A, Ellinger J, Rogenhofer S, Buettner R, Wernert N.

Mol Med Rep. 2012 Jan;5(1):32-6. doi: 10.3892/mmr.2011.628. Epub 2011 Oct 11.

PMID:
21993862
28.

Identification of immunity-related genes in prostate cancer and potential role of the ETS family of transcription factors in their regulation.

Shaikhibrahim Z, Lindstrot A, Ellinger J, Rogenhofer S, Buettner R, Wernert N.

Int J Mol Med. 2011 Nov;28(5):799-807. doi: 10.3892/ijmm.2011.771. Epub 2011 Aug 10.

PMID:
21833467
29.

Analysis of laser-microdissected prostate cancer tissues reveals potential tumor markers.

Shaikhibrahim Z, Lindstrot A, Buettner R, Wernert N.

Int J Mol Med. 2011 Oct;28(4):605-11. doi: 10.3892/ijmm.2011.746. Epub 2011 Jul 8.

PMID:
21743959
30.

Differential expression of ETS family members in prostate cancer tissues and androgen-sensitive and insensitive prostate cancer cell lines.

Shaikhibrahim Z, Lindstrot A, Langer B, Buettner R, Wernert N.

Int J Mol Med. 2011 Jul;28(1):89-93. doi: 10.3892/ijmm.2011.672. Epub 2011 Apr 13.

PMID:
21491078
31.

Comprehensive gene expression microarray analysis of Ets-1 blockade in PC3 prostate cancer cells and correlations with prostate cancer tissues: Insights into genes involved in the metastatic cascade.

Shaikhibrahim Z, Lindstrot A, Langer B, Buettner R, Wernert N.

Int J Mol Med. 2011 Jun;27(6):811-9. doi: 10.3892/ijmm.2011.652. Epub 2011 Mar 21.

PMID:
21424114
32.

Ets-1 is implicated in the regulation of androgen co-regulator FHL2 and reveals specificity for migration, but not invasion, of PC3 prostate cancer cells.

Shaikhibrahim Z, Langer B, Lindstrot A, Florin A, Bosserhoff A, Buettner R, Wernert N.

Oncol Rep. 2011 Apr;25(4):1125-9. doi: 10.3892/or.2011.1156. Epub 2011 Jan 21.

PMID:
21258770
33.

Med8, Med18, and Med20 subunits of the Mediator head domain are interdependent upon each other for folding and complex formation.

Shaikhibrahim Z, Rahaman H, Wittung-Stafshede P, Björklund S.

Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20728-33. doi: 10.1073/pnas.0907645106. Epub 2009 Nov 23.

34.

Functional and physical interactions within the middle domain of the yeast mediator.

Hallberg M, Hu GZ, Tronnersjö S, Shaikhibrahim Z, Balciunas D, Björklund S, Ronne H.

Mol Genet Genomics. 2006 Aug;276(2):197-210. Epub 2006 Jun 7.

PMID:
16758199

Supplemental Content

Loading ...
Support Center